Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.

Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure. 

Execs offer a guarded reaction, noting the need for continued dialogue, but emphasize the dire threat that the pricing program poses to the pharma business model.

Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.